Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users
NCT06594068
Recruiting
Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users (PRIMULA Lac) is a Post Marketing Requirements (PMR) study designed to fulfill the FDA post-marketing requirements. The study will collect data about the presence of anifrolumab in human breast milk and serum (maternal and infant) among lactating individuals who receive anifrolumab therapeutically.
Gender:
FEMALE
Ages:
Between 18 years and 130 years
Trial Updated:
07/15/2025
Locations: Research Site, Las Vegas, Nevada
Conditions: Systemic Lupus Erythematosus
Register for Updates
Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
NCT06596291
Recruiting
This is a first-in-human, Phase 1b/2a, open-label, dose-escalation study of a single treatment course consisting of multiple intradetrusor injections of EG110A in male and female adult participants with Neurogenic Detrusor Overactivity (NDO)-related incontinence following Spinal Cord Injury (SCI), who have persistent incontinence after standard of care therapy and who perform Clear Intermittent Catheterization (CIC) on a regular basis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/15/2025
Locations: Rancho Los Amigos National Rehabilitation Center, Downey, California +3 locations
Conditions: Neurogenic Detrusor Overactivity, Spinal Cord Injuries
Register for Updates
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
NCT06600321
Recruiting
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of ALN-BCAT as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Clinical Trial Site, Los Angeles, California +10 locations
Conditions: Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Register for Updates
Robotic Apparel to Prevent Freezing of Gait in Parkinson Disease
NCT06602544
Recruiting
Freezing-of-gait (FoG) in Parkinson Disease (PD) is one of the most vivid and disturbing gait phenomena in neurology. Often described by patients as a feeling of "feet getting glued to the floor," FoG is formally defined as a "brief, episodic absence or marked reduction of forward progression of the feet despite the intention to walk." This debilitating gait phenomena is very common in PD, occurring in up to 80% of individuals with severe PD. When FoG arrests walking, serious consequences can oc... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/15/2025
Locations: Harvard Science and Engineering Complex, Allston, Massachusetts +1 locations
Conditions: Parkinson Disease (PD)
Register for Updates
A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
NCT06614192
Recruiting
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events disease activity when comparing intravenously (IV) infused telisotuzumab adizutecan to trifluridine and tipiracil (LONSURF) oral tablets plus IV infused bevacizumab in adult participants with c-Met protein above cutoff level refractory metastatic colorectal cancer (mCRC). Telisotuzumab adizutecan is an investigational drug being developed for th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: City of Hope National Medical Center /ID# 267875, Duarte, California +50 locations
Conditions: Metastatic Colorectal Cancer
Register for Updates
HealthyTogether: RCT of a Dyadic Weight Management Intervention
NCT06619041
Recruiting
Four in five Veterans have overweight or obesity. However, few eligible Veterans achieve meaningful weight loss in VA's national MOVE! Weight Management Program. Family and friends strongly influence a person's health behaviors and weight. Including a close family member or friend in weight management may improve weight management outcomes. This study will test whether an 14-week, 8-session virtual weight management program that includes Veterans and a support person (e.g., family member or frie... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Rocky Mountain Regional VA Medical Center, Aurora, CO, Aurora, Colorado +1 locations
Conditions: Obesity, Overweight
Register for Updates
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
NCT06619860
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/15/2025
Locations: Cullman Clinical Trials, Cullman, Alabama +40 locations
Conditions: Diabetic Peripheral Neuropathic Pain
Register for Updates
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06625320
Recruiting
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +57 locations
Conditions: Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Register for Updates
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity
NCT06638671
Recruiting
Metformin is the most prescribed blood sugar (glucose)-lowering medication for patients diagnosed with type 2 diabetes mellitus (T2DM). Metformin stimulates glucose uptake in skeletal muscle similar to the effects of exercise, though, some studies report that metformin may decrease exercise capacity. The main question this study looks to answer is: • Does metformin alter exercise capacity? Participants will: * Complete 5 exercise tests on a stationary bike. * Undergo a body composition test.... Read More
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
07/15/2025
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Exercise Capacity, Metformin
Register for Updates
Vaccine Confidence Study Among Historically Marginalized Racial and Ethnic Groups
NCT06639386
Recruiting
Achieving optimal vaccination rates is vital for protecting the health and well-being of all individuals. This specific study focuses on the MMR and RSV vaccines in pregnancy and early childhood, which have been shown to reduce RSV and MMR-related illnesses, hospitalizations, and deaths. Efforts to improve vaccination rates have not been equally effective across the entire population; this has resulted in poorer outcomes from interventions for certain populations who are vaccine-hesitant. This... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Vaccine Hesitancy, Vaccine Refusal
Register for Updates
Healing Track Clinical Trial
NCT06641102
Recruiting
This is a randomized clinical trial to evaluate a digital pain reprocessing therapy (PRT) intervention for chronic back pain (CBP). The purpose of this research is to test whether a new digital treatment for chronic pain works as well as traditional treatments for chronic back pain (CBP). Some people with CBP experienced side effects from other treatments, or previous treatments did not relieve pain, so this research aims to see if a digital therapy is a better option for CBP. This study will... Read More
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
07/15/2025
Locations: Icahn School of Medicine at Mount Sinai - Abilities Research Center, New York, New York
Conditions: Chronic Back Pain
Register for Updates
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
NCT06660810
Recruiting
The proposed study is designed to treat locally advanced soft tissue sarcoma (STS) subtypes with neoadjuvant talimogene laherparepvec (TVEC) and preoperative external beam radiation therapy (EBRT).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: University of Iowa, Iowa City, Iowa
Conditions: Soft Tissue Sarcoma, Sarcoma,Soft Tissue
Register for Updates